SynthesisOncotarget2017
Prognostic value of microRNAs in osteosarcoma: A meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis.Frontiers in genetics · 2020Pooled it
- Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma.PloS one · 2019Pooled it
- Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis.Yonsei medical journal · 2018Pooled it
- KLF9 regulates miR-338-3p/NRCAM axis to block the progression of osteosarcoma cells.Journal of Cancer · 2022Article
- Article
- Analysis of a Preliminary microRNA Expression Signature in a Human Telangiectatic Osteogenic Sarcoma Cancer Cell Line.International journal of molecular sciences · 2021Article
- Long Noncoding RNA CCDC144NL-AS1 Promotes the Oncogenicity of Osteosarcoma by Acting as a Molecular Sponge for microRNA-490-3p and Thereby Increasing HMGA2 Expression.OncoTargets and therapy · 2021Article
- MicroRNA-652 promotes cell proliferation and osteosarcoma invasion by directly targeting KLF9.Experimental and therapeutic medicine · 2020Article
- The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer.Journal of bone oncology · 2020Article
- Ailanthone: A novel potential drug for treating human cancer.Oncology letters · 2020Review
- LINC00266-1/miR-548c-3p/SMAD2 feedback loop stimulates the development of osteosarcoma.Cell death & disease · 2020Article
- Long noncoding RNAAging · 2019Article
- MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway.International journal of molecular medicine · 2019Article
- Long noncoding RNAAging · 2019Article
- Prognostic scoring system for osteosarcoma using network-regularized high-dimensional Cox-regression analysis and potential therapeutic targets.Journal of cellular physiology · 2019Article
- MicroRNAs in Bone Metastasis.Current osteoporosis reports · 2019Review
- MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.Journal of cellular and molecular medicine · 2019Article
- MicroRNA-206 Reduces Osteosarcoma Cell MalignancyYonsei medical journal · 2019Article
- MicroRNA-559 plays an inhibitory role in the malignant progression of glioblastoma cells by directly targeting metadherin.OncoTargets and therapy · 2019Article
- microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targetingAmerican journal of cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.
methodsSources from MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) were searched. Studies of osteosarcoma with results of miRNA and studies that reported survival data were included and two authors performed the data extraction independently. Any discrepancies were resolved by a consensus. The outcome was overall survival and event-free survival assessed using hazard ratios (HRs).
resultsAfter reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible in this study. The pooled HR for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p<0.00001, I2=79%) for patients of osteosarcoma with lower expression of miRNA. However, the pooled HR for events was not significant (HR 0.97, 0.63-1.48, p=0.87, χ2=72.65, p<0.00001, I2=79%). In pathway analysis of miRNAs, miRNA449a, 199-5p, 542-5p have common target genes.
conclusionsExpression level of miRNA in patients of osteosarcoma is important as a prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.